Pasithea Therapeutics Corp. (KTTA) Financials
Annual revenue, profitability and per-share results for Pasithea Therapeutics Corp., as reported in SEC filings.
Revenue • FY2025
$0
Net income • FY2025
-$20.43M
▼ 46.9%YoY
Diluted EPS • FY2025
$-2.91
▲ 77.1%YoY
Annual income statement
| Period | Revenue | Net income | Gross profit | Dil. EPS | Free cash flow | Op. margin | Rev. growth |
|---|---|---|---|---|---|---|---|
| FY2025 | $0 | -$20.43M | — | $-2.91 | — | — | — |
| FY2024 | $0 | -$13.9M | — | $-12.69 | — | — | — |
| FY2023 | $0 | -$15.96M | — | $-0.42 | -$12.85M | — | -100.0% |
| FY2022 | $486.6K | -$13.94M | $373.4K | $-0.53 | -$14.94M | -3045.1% | +3130.4% |
Figures as reported in Pasithea Therapeutics Corp.'s 10-K filings on SEC EDGAR. Fiscal years may differ from calendar years.
Never miss a KTTA filing.
Get an email when KTTA files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Source: SEC EDGAR.